The drugs effects go beyond LDL-lowering in ways that might potentially benefit hospitalized patients with COVID-19, at least those who are sickest, preliminary results suggest.
/PRNewswire/ According to a new report published by UnivDatos Markets Insights, the Biosimilars Market was valued at USD 13 billion in 2020 and is expected.
Regulatory approval for first patient study of first non-antibiotic macrolideREYKJAVIK, Iceland, November 14, 2022 / B3C newswire / EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to.
Findings from the first clinical trial program comparing the use of Teva’s Digihaler® System to standard of care in asthma management will be presented across six abstractsTEL AVIV, Israel & PARSIPPANY, N.J. (BUSINESS WIRE) Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NY.
There was a strong, but not statistically significant, signal of reduced spinal structural damage with the combination of a selective COX-2 inhibitor and a TNF inhibitor in axial spondyloarthritis.